Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GXO Logistics Inc (GXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GXO Logistics Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.3 (market cap $39.89B), while GXO Logistics Inc trades at $49.51 (market cap $5.82B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.9× GXO Logistics Inc's market cap, and GXO Logistics Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GXO | |
|---|---|---|
Market Cap | $39.89B | $5.82B |
Sector | Health | Industrials |
52-Week High | $491.22 | $65.59 |
52-Week Low | $278.09 | $45.52 |
Enterprise Value | $38.15B | $10.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GXO Logistics trades at $50.61, down 2.15% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters and holds a low P/S ratio of 0.43. Recent news highlights new partnership renewals and expansion in Europe, supporting growth prospects.
Wall Street analysts are overwhelmingly bullish with an 88.89% buy rating and a $69.33 consensus price target, implying significant upside. Key risks include competitive pressures from Amazon and reliance on retail clients, but improving profit margins and a record sales pipeline provide a positive fundamental outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
